The spirostenol (22R, 25R)-20α-spirost-5-en-3β-yl hexanoate blocks mitochondrial uptake of Aβ in neuronal cells and prevents Aβ-induced impairment of mitochondrial function

Steroids

Volumn 71, Issue 8, 2006, Pages 725-735

  Tillement, Laurent ^a   Lecanu, Laurent ^a   Yao, Wenguo ^a   Greeson, Janet ^b   Papadopoulos, Vassilios ^a  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Samaritan Pharmaceuticals   (United States)

Author keywords

Amyloid peptide; Alzheimer's disease; Neuroprotection; Neurosteroids

Indexed keywords

20ALPHA SPIROST 5 EN 3BETA YL HEXANOATE; AMYLOID BETA PROTEIN[1-42]; ARSENOSOBENZENE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; HEXANOIC ACID; SP 233; TOXIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG BINDING; FOREBRAIN; HUMAN; HUMAN CELL; MEMBRANE PERMEABILITY; MITOCHONDRIAL RESPIRATION; MITOCHONDRIAL TOXICITY; MITOCHONDRION; NERVE CELL; NEUROBLASTOMA CELL; NEUROPROTECTION; NONHUMAN; OXIDATIVE PHOSPHORYLATION; PROTEIN TRANSPORT; RAT; RESPIRATORY CHAIN;

ADENOSINE TRIPHOSPHATASES; AMYLOID BETA-PROTEIN; ANIMALS; BRAIN; CAPROATES; CARBONYL CYANIDE P-TRIFLUOROMETHOXYPHENYLHYDRAZONE; CARRIER PROTEINS; CYCLOSPORINE; HUMANS; MEMBRANE PROTEINS; MITOCHONDRIA; MODELS, BIOLOGICAL; MULTIPROTEIN COMPLEXES; NEUROBLASTOMA; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; RATS; RESPIRATION; SPIRO COMPOUNDS; SPIROSTANS; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 33745608709     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.steroids.2006.05.003     Document Type: Article

References (39)

1. Golde T.E., Estus S., Younkin L.H., Selkoe D.J., and Younkin S.G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255 5045 (1992) 688-689
2. Eckert G.P., Wood W.G., and Muller W.E. Effects of aging and β-amyloid on the properties of brain synaptic and mitochondrial membranes. J Neural Transm 108 (2001) 1051-1064
3. Kroemer G., and Reed J.C. Mitochondrial control of cell death. Nat Med 6 (2000) 513-519
4. Manfredi G., and Beal M.F. The role of mitochondria in the pathogenesis of neurodegenerative diseases. Brain Pathol 10 (2000) 462-472
5. Moreira P.I., Santos M.S., Moreno A., and Oliveira C. Amyloid beta-peptide promotes permeability transition pore in brain mitochondria. Biosci Rep 21 (2001) 789-800
6. Moreira P.I., Santos M.S., Moreno A., Rego A.C., and Oliveira C. Effect of amyloid beta-peptide on permeability transition pore: a comparative study. J Neurosci Res 69 (2002) 257-267
7. Crompton M. The mitochondrial permeability transition pore and its role in cell death. Biochem J 341 Pt 2 (1999) 233-249
8. Sergeant N., Wattez A., Galvan-Valencia M., Ghestem A., David J.P., Lemoine J., et al. Association of ATP synthase alpha-chain with neurofibrillary degeneration in Alzheimer's disease. Neuroscience 117 (2003) 293-303
9. Volicer L., and Crino P.B. Involvement of free radicals in dementia of the Alzheimer type: a hypothesis. Neurobiol Aging 11 (1990) 567-571
10. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative disease?. Ann Neurol 31 (1992) 119-130
11. Pereira C., Santos M.S., and Oliveira C. Involvement of oxidative stress on the impairment of energy metabolism induced by Abeta peptides on PC12 cells: protection by antioxidants. Neurobiol Dis 6 (1999) 209-219
12. Kim S.H., Vlkolinsky R., Cairns N., and Lubec G. Decreased levels of complex III core protein 1 and complex V beta chain in brains from patients with Alzheimer's disease and Down syndrome. Cell Mol Life Sci 57 (2000) 1810-1816
13. Baloyannis S.J., Costa V., and Michmizos D. Mitochondrial alterations in Alzheimer's disease. Am J Alzheimers Dis Other Demen 19 2 (2004) 89-93
14. Abramov A.Y., Canevari L., and Duchen M.R. Beta-amyloid peptides induce mitochondrial dysfunction and oxidative stress in astrocytes and death of neurons through activation of NADPH oxidase. J Neurosci 24 (2004) 565-575
15. Lustbader J.W., Cirilli M., Lin C., et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer's disease. Science 304 (2004) 448-452
16. Busciglio J., Pelsman A., Wong C., Pigino G., Yuan M., Mori H., et al. Altered metabolism of the amyloid beta precursor protein is associated with mitochondrial dysfunction in Down's syndrome. Neuron 33 (2002) 677-688
17. Rodrigues C.M.P., Sola S., Brito M.A., Brondino C.D., Brites D., and Moura J.J.G. Amyloid β-peptide disrupts mitochondrial membrane lipid and protein structure: protective role of tauroursodeoxycholate. Biochem Biophys Res Commun 281 (2001) 468-474
18. Aliev G., Seyidova D., Lamb B.T., Obrenovitch M.E., Siedlak S.L., Vinters H.V., et al. Mitochondria and vascular lesions as a central target for the development of Alzheimer's disease and Alzheimer disease-like pathology in transgenic mice. Neurol Res 25 6 (2003) 665-674
19. Alvarez G., Ramos M., Ruiz F., Satrustegui J., and Bogonez E. Pyruvate protection against beta-amyloid-induced neuronal death: role of mitochondrial redox state. J Neurosci Res 73 2 (2003) 260-269
20. Casley C.S., Canevari L., Land J.M., Clark J.B., and Sharpe M.A. β-Amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80 (2002) 91-100
21. Casley C.S., Land J.M., Sharpe M.A., Clark J.B., Duchen M.R., and Canevari L. Beta-amyloid fragment 25-35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 10 (2002) 258-267
22. Lecanu L., Yao W., Teper G.L., Yao Z.X., Greeson J., and Papadopoulos V. Identification of naturally occurring spirostenols preventing beta-amyloid-induced neurotoxicity. Steroids 69 (2004) 1-16
23. Zini R., Simon N., Morin C., d'Athis P., and Tillement J.P. Inhibition of rat cerebral mitochondrial respiration by cyclosporins A, D, and G and restoration with trimetazidine. C R Acad Sci III 319 (1996) 1087-1092
24. Smith C.M., and Swash M. Possible biochemical basis of memory disorder in Alzheimer disease. Ann Neurol 3 6 (1978) 471-473
25. Tariot P., and Winblad B. In: Iqbal K., Sisodia S.S., and Winblad B. (Eds). Galantamine, a novel treatment for Alzheimer's disease: a review of long-term benefits to patients and caregivers in Alzheimer's disease: advances in etiology, pathogenesis and therapeutics (2001), John Wiley & Sons, Chichester 705-723
26. Waldemar G., Winblad B., Engedal K., Soininen H., Verhey F., Wimo A., et al. In: Iqbal K., Sisodia S.S., and Winblad B. (Eds). Benefits of donepezil on cognition, function and neuropsychiatric symptoms in patients with mild and moderate Alzheimer's disease over one year, in Alzheimer's disease: advances in etiology, pathogenesis and therapeutics (2001), John Wiley & Sons, Chichester 725-738
27. Grossberg G., Irwin P., Satlin A., Mesenbrink P., and Spiegel R. Rivastigmine in Alzheimer disease: efficacy over two years. Am J Geriatr Psychiatry 12 (2004) 420-431
28. Livingston G., and Katona C. The place of memantine in the treatment of Alzheimer's disease: a number needed to treat analysis. Int J Geriatr Psychiatry 19 (2004) 919
29. Schulz J.B., Matthews R.T., Klockgether T., Dichgans J., and Beal M.F. The role of mitochondrial dysfunction and neuronal nitric oxide in animal models of neurodegenerative diseases. Mol Cell Biochem 174 (1997) 193-197
30. Beal M.F. Energetics in the pathogenesis of neurodegenerative diseases. Trends Neurosci 23 (2000) 298-304
31. Kaneko I., Yamada N., Sakuraba Y., Kamenosono M., and Tutumi S. Suppression of mitochondrial succinate dehydrogenase, a primary target of beta-amyloid, and its derivative recemized at Ser residue. J Neurochem 65 (1995) 2585-2593
32. Canevari L., Clark J.B., and Bates T.E. β-amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 457 (1999) 131-134
33. Bachurin S.O., Shevtsova E.P., Kireeva E.G., Oxenkrug G.F., and Sablin S.O. Mitochondria as a target for neurotoxins and neuroprotective agents. Ann NY Acad Sci 993 (2003) 334-344
34. Fernandez-Vizarra P., Fernandez A.P., Castro-Blanco S., Serrano J., Bentura M.L., Martinez-Murillo R., et al. Intra- and extracellular Aβ and PHF in clinically evaluated cases of Alzheimer's disease. Histol Histopathol 19 (2004) 823-844
35. Korge P., Goldhaber J.L., and Weiss J.N. Phenylarsine oxide induces mitochondrial permeability transition, hypercontracture, and cardiac cell death. Am J Physiol Heart Circ Physiol 250 5 (2001) H2203-H2213
36. Kremer J.J., Sklansky D.J., and Murphy R.M. Profile of changes in lipid bilayer structure caused by beta-amyloid peptide. Biochemistry 40 (2001) 8563-8571
37. Mecocci P., Cherubini A., Beal M.F., Cecchetti R., Chionne F., Polidori M.C., et al. Altered mitochondrial membrane fluidity in AD brain. Neurosci Lett 207 (1996) 129-132
38. Snyder E.M., Nong Y., Almeida G., Paul S., Moran T., Choi E.Y., et al. Regulation of NMDA receptor trafficking by amyloid-β. Nat Neurosci 8 (2005) 1051-1058
39. Tsukatani H., Takauchi K., Yoshida J., Yamata S., Tokumura A., and Hamaguchi C. Isolation of diosgenin [(25R)-spirost-5-en-3beta-ol] from a lysate of a new hypotensive phospholipid occurring in bovine brain. J Neurochem 44 20 (1985) 658-661